Overview

Expanded Access Program of Sofosbuvir With Ribavirin and With or Without Pegylated Interferon in Aggressive Post-transplant Hepatitis C

Status:
Approved for marketing

Trial end date:
1969-12-31

Target enrollment:

Participant gender:

Summary

This is a single arm, open-label study which will be opened at specific clinical sites at the request of an investigator for the treatment of individual subjects for whom there are no other treatment options. Subjects will be treated for 24 weeks with sofosbuvir (400mg QD) with RBV; pegylated interferon may be added at the discretion of the investigator.

Details

Lead Sponsor:

Gilead Sciences

Treatments:

Interferons
Molecular Mechanisms of Pharmacological Action
Ribavirin
Sofosbuvir